What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs), split across three businesses. Domestic Formulations contributed 82% of FY26 sales and sells branded medicines in India, including antibiotics like Zifi, rehydration brand Electral and energy drink Enerzal, through prescriptions and over-the-counter channels. Export Formulations sells generic drugs in overseas markets, primarily the United States, and received US FDA approvals for Fluconazole Tablets and Cefixime for Oral Suspension USP during FY26. The API business manufactures and sells bulk drug ingredients to other pharmaceutical companies. FY26 consolidated revenue was Rs. 2,171 crore with EBITDA margin of 20.2%, and the Q4 FY26 quarter alone brought in Rs. 585 crore at 18.9% year-on-year growth, led by exports. Operating costs are dominated by materials (26.5% of revenue), employee costs (22.2%) and other operating expenses (29.1%), with depreciation at 2.7% and capex at 8.6% of revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from FDC LIMITED's filed financials and exchange disclosures
FDC LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol FDC.
Yes. Over the trailing twelve months FDC LIMITED reported a net profit of ₹293 Cr on revenue of ₹2,190 Cr.
Yes. The dividend yield is 1.46% at the current price. It paid out 29% of its profit as dividend in FY26.
Effectively yes. It holds ₹49 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, FDC LIMITED ranks 54 of 169 in Pharmaceuticals — cheaper than 69% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session FDC LIMITED moves 1.02% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by FDC LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
